3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow upamostat: new trials by email Literature Review of upamostat trials Research Report on upamostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 Upamostat, Placebo (PO) - SARS-CoV-2 | Phase 2 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 92 | 2024-01-29 | 2026-04-17 |
| Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer WX-671, placebo - Metastatic Breast Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 132 | 2008-07-01 | 2014-02-28 |
| Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671 - Pancreatic Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 95 | 2007-04-01 | 2012-03-29 |
Breast Neoplasms (1) · COVID-19 (1) · Pancreatic Neoplasms (1)
Heidelberg Pharma AG (2) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1)
Germany (2) · United States (2) · Belgium (1) · Brazil (1) · Hungary (1) · Israel (1) · Italy (1) · Russia (1) · South Africa (1) · Spain (1) · Thailand (1) · Uganda (1) · Ukraine (1)
Carola Mala, PhD (1) · Lori Goldstein, MD (1) · Nadia Harbeck, MD (1)